Clinical Trials
13 trialsNCT05976997 2026-05-18
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)
Huazhong University of Science and Technology
Phase 2 Recruiting
NCT04331119 2026-05-06
Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas
Washington University School of Medicine
Phase 2 Terminated
NCT04803201 2026-05-06
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT03961672 2026-01-05
Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT07293403 2025-12-19
Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT05057247 2025-10-31
Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Completed
NCT03372057 2025-03-07
PRIMO
SecuraBio
Phase 2 Completed
NCT02711852 2023-09-11
A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)
SecuraBio
Phase 2 Completed
NCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT04209621 2022-03-09
Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02605694 2021-03-17
FRESCO
SecuraBio
Phase 2 Withdrawn
NCT04707079 2021-01-13
A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT02028039 2014-01-06
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn